Federal (United States) · Session law
Title III
55 sections
55 sections
- Pub. L. 114-255, div. A, tit. III, subtit. A, sec. 3001PATIENT EXPERIENCE DATA.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. A, sec. 3002PATIENT-FOCUSED DRUG DEVELOPMENT GUIDANCE.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. A, sec. 3003STREAMLINING PATIENT INPUT.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. A, sec. 3004REPORT ON PATIENT EXPERIENCE DRUG DEVELOPMENT.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. B, sec. 3011QUALIFICATION OF DRUG DEVELOPMENT TOOLS.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. B, sec. 3012TARGETED DRUGS FOR RARE DISEASES.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. B, sec. 3013REAUTHORIZATION OF PROGRAM TO ENCOURAGE TREATMENTS FOR RARE PEDIATRIC DISEASES.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. B, sec. 3014GAO STUDY OF PRIORITY REVIEW VOUCHER PROGRAMS.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. B, sec. 3015AMENDMENTS TO THE ORPHAN DRUG GRANTS.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. B, sec. 3016GRANTS FOR STUDYING CONTINUOUS DRUG MANUFACTURING.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. C, sec. 3021NOVEL CLINICAL TRIAL DESIGNS.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. C, sec. 3022REAL WORLD EVIDENCE.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. C, sec. 3023PROTECTION OF HUMAN RESEARCH SUBJECTS.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. C, sec. 3024INFORMED CONSENT WAIVER OR ALTERATION FOR CLINICAL INVESTIGATIONS.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. D, sec. 3031SUMMARY LEVEL REVIEW.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. D, sec. 3032EXPANDED ACCESS POLICY.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. D, sec. 3033ACCELERATED APPROVAL FOR REGENERATIVE ADVANCED THERAPIES.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. D, sec. 3034GUIDANCE REGARDING DEVICES USED IN THE RECOVERY, ISOLATION, OR DELIVERY OF REGENERATIVE ADVANCED THERAPIES.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. D, sec. 3035REPORT ON REGENERATIVE ADVANCED THERAPIES.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. D, sec. 3036STANDARDS FOR REGENERATIVE MEDICINE AND REGENERATIVE ADVANCED THERAPIES.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. D, sec. 3037HEALTH CARE ECONOMIC INFORMATION.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. D, sec. 3038COMBINATION PRODUCT INNOVATION.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. E, sec. 3041ANTIMICROBIAL RESISTANCE MONITORING.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. E, sec. 3042LIMITED POPULATION PATHWAY.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. E, sec. 3043PRESCRIBING AUTHORITY.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. E, sec. 3044SUSCEPTIBILITY TEST INTERPRETIVE CRITERIA FOR MICROORGANISMS; ANTIMICROBIAL SUSCEPTIBILITY TESTING DEVICES.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. F, sec. 3051BREAKTHROUGH DEVICES.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. F, sec. 3052HUMANITARIAN DEVICE EXEMPTION.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. F, sec. 3053RECOGNITION OF STANDARDS.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. F, sec. 3054CERTAIN CLASS I AND CLASS II DEVICES.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. F, sec. 3055CLASSIFICATION PANELS.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. F, sec. 3056INSTITUTIONAL REVIEW BOARD FLEXIBILITY.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. F, sec. 3057CLIA WAIVER IMPROVEMENTS.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. F, sec. 3058LEAST BURDENSOME DEVICE REVIEW.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. F, sec. 3059CLEANING INSTRUCTIONS AND VALIDATION DATA REQUIREMENT.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. F, sec. 3060CLARIFYING MEDICAL SOFTWARE REGULATION.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. G, sec. 3071SILVIO O. CONTE SENIOR BIOMEDICAL RESEARCH AND BIOMEDICAL PRODUCT ASSESSMENT SERVICE.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. G, sec. 3072HIRING AUTHORITY FOR SCIENTIFIC, TECHNICAL, AND PROFESSIONAL PERSONNEL.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. G, sec. 3073ESTABLISHMENT OF FOOD AND DRUG ADMINISTRATION INTERCENTER INSTITUTES.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. G, sec. 3074SCIENTIFIC ENGAGEMENT.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. G, sec. 3075DRUG SURVEILLANCE.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. G, sec. 3076REAGAN-UDALL FOUNDATION FOR THE FOOD AND DRUG ADMINISTRATION.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. H, sec. 3081MEDICAL COUNTERMEASURE GUIDELINES.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. H, sec. 3082CLARIFYING BARDA CONTRACTING AUTHORITY.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. H, sec. 3083COUNTERMEASURE BUDGET PLAN.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. H, sec. 3084MEDICAL COUNTERMEASURES INNOVATION.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. H, sec. 3085STREAMLINING PROJECT BIOSHIELD PROCUREMENT.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. H, sec. 3086ENCOURAGING TREATMENTS FOR AGENTS THAT PRESENT A NATIONAL SECURITY THREAT.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. H, sec. 3087PAPERWORK REDUCTION ACT WAIVER DURING A PUBLIC HEALTH EMERGENCY.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. H, sec. 3088CLARIFYING FOOD AND DRUG ADMINISTRATION EMERGENCY USE AUTHORIZATION.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. I, sec. 3091PREDICTABLE REVIEW TIMELINES OF VACCINES BY THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. I, sec. 3092REVIEW OF PROCESSES AND CONSISTENCY OF ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES RECOMMENDATIONS.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. I, sec. 3093ENCOURAGING VACCINE INNOVATION.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. J, sec. 3101TECHNICAL CORRECTIONS.Enacted
- Pub. L. 114-255, div. A, tit. III, subtit. J, sec. 3102COMPLETED STUDIES.Enacted